McKesson (MCK Quick QuoteMCK - Free Report) reported $110.96 billion in revenue for the quarter ended September 2026, representing a year-over-year increase of 7.6%. EPS of $11.68 for the same period compares to $9.86 a year ago.

The reported revenue represents a surprise of +0.77% over the Zacks Consensus Estimate of $110.11 billion. With the consensus EPS estimate being $10.69, the EPS surprise was +9.26%.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how McKesson performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Revenue- North American Pharmaceutical: $91.36 billion compared to the $91.5 billion average estimate based on two analysts.
• Revenue- Prescription Technology Solutions: $1.52 billion versus $1.46 billion estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +10.5% change.
• Revenue- Oncology & Multispecialty: $14.98 billion versus the two-analyst average estimate of $13.83 billion.
• Revenue- Medical-Surgical Solutions: $3.1 billion versus the two-analyst average estimate of $3.04 billion. The reported number represents a year-over-year change of +5.1%.
• Adjusted Operating Profit- North American Pharmaceutical: $1.04 billion compared to the $915.71 million average estimate based on two analysts.
• Adjusted Operating Profit- Medical-Surgical Solutions: $225 million compared to the $261.24 million average estimate based on two analysts.
• Adjusted Operating Profit- Corporate: $-147 million versus $-160.82 million estimated by two analysts on average.
• Adjusted Operating Profit- Oncology & Multispecialty: $427 million versus the two-analyst average estimate of $400.41 million.
• Adjusted Operating Profit- Prescription Technology Solutions: $307 million versus $295.09 million estimated by two analysts on average.

View all Key Company Metrics for McKesson here>>>

Shares of McKesson have returned +8.5% over the past month versus the Zacks S&P 500 composite's -2% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.